Pfizer finds generics partner for China; Obama targets opioid abuse;

> Pfizer and Chinese drugmaker Zhejiang Hisun Pharmaceuticals are partnering on the manufacturing and marketing of branded generics in China. Story

> The White House is targeting extended-release opioids in a campaign to reduce abuse and misuse of prescription drugs. Story

> Global Health Ventures has tapped Canadian CMO Confab for production of clinical supplies of X-Excite, a candidate treatment for sexual enhancement. Article

> Taro Pharmaceuticals Canada is recalling Docusate sodium capsules from the Canadian market due to possibility of contamination with the bacterial organism cronobacter (enterobacter) sakazakii. Item

> Elite Pharmaceuticals will provide lab stability studies, manufacturing and packaging for two generic products under a supply pact with Mikah Pharma. Report

> Manufacturing remediation charges from its U.S.-unit Caraco continue to be a drag on operating profit margin at Sun Pharma. Article

> A $1,000 investment in fake drugs can return $30,000, 10 times the typical profit from the same investment in heroin. News

> Startup CertiRx has developed technology to embed a tiny tags made of excipients into drugs, allowing for identification and authentication. Story

> French vaccine maker Sanofi Pasteur has relieved the founder and managing director of its Indian subsidiary, Shantha Biotech, of executive responsibilities following the collapse of a promising vaccine. Item

> BioVigilant Systems has unveiled a rapid biologic detection system for real-time environmental air monitoring in pharma manufacturing environments. Article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.